The supply of almost every Schedule II opioid manufactured in the United States will be reduced 25% or more in 2017, as required by the Drug Enforcement Administration (DEA).
The new quota will be sufficient to meet the estimated medical, scientific, research, industrial and export needs for the year, and for the maintenance of reserve stocks, said Demetra Ashley, associate deputy administrator of the DEA Diversion Control Division. Affected drugs include oxycodone, hydrocodone (reduced to 66%